6-methoxy-2-(3-methyl-4-nitrophenyl)benzo[d]thiazole | 247080-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-methoxy-2-(3-methyl-4-nitrophenyl)benzo[d]thiazole
• 英文别名: 6-Methoxy-2-(3-methyl-4-nitrophenyl)-1,3-benzothiazole
• CAS: 247080-17-7
• 化学式: C₁₅H₁₂N₂O₃S
• 分子量: 300.338
• InChiKey: DFMHJZBABQUIPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  96.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-methoxy-2-(3-methyl-4-nitrophenyl)benzo[d]thiazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以95%的产率得到4-(6-methoxybenzothiazol-2-yl)-2-methylphenylamine
  参考文献：
  名称：

  2-（4-氨基苯基）苯并噻唑衍生物作为光敏剂的合成及生物学评价

  摘要：

  使用外源光敏剂的光动力疗法（PDT）目前已被批准用于治疗基底细胞癌（BCC）。2-（4-氨基苯基）苯并噻唑（6）由发色结构组成，可吸收UVA（315-400 nm）中的光。这些结果鼓励我们设计和合成各种2-苯基苯并噻唑（6）。在本文中研究了UVC激活的6在BCC细胞中诱导的光敏效应所涉及的凋亡机制。用6 -UVA处理的细胞显示出一些凋亡特征，包括亚G1群体的增加，膜联蛋白V结合的显着增加以及caspase-3的激活。6-UVA诱导线粒体膜电位（Δ降低ψ公吨），并通过增强的ROS产生和胞外信号调节激酶（ERK）和p38 MAPK表达的促进磷酸ATP。这些结果表明6- UVA在涉及ERK和p38活化的线粒体过程中引起光敏作用，并最终导致BCC细胞凋亡。

  DOI：

  10.1016/j.bmc.2010.04.082
• 作为产物：
  描述：

  3-甲基-4-硝基苯甲酰氯 在 劳森试剂 、 吡啶 、 sodium hydroxide 、 potassium hexacyanoferrate(III) 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 14.0h， 生成 6-methoxy-2-(3-methyl-4-nitrophenyl)benzo[d]thiazole
  参考文献：
  名称：

  2-Arylaminobenzothiazole-arylpropenone缀合物作为微管蛋白聚合抑制剂

  摘要：

  基于5F-203设计了一系列新的2-芳基氨基苯并噻唑-芳基丙烯酮共轭物，并对其细胞毒性和抑制微管蛋白聚合作用进行了评估。

  DOI：

  10.1039/c6md00562d

文献信息

• 2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors
  作者：A. V. Subba Rao、Bala Bhaskara Rao、Satish Sunkari、Siddiq Pasha Shaik、Bajee Shaik、Ahmed Kamal

  DOI：10.1039/c6md00562d

  日期：——

  A new series of 2-arylaminobenzothiazole-arylpropenone conjugates were designed based on 5F-203, synthesized and evaluated for their cytotoxic potency as well as inhibition of tubulin polymerization.

  基于5F-203设计了一系列新的2-芳基氨基苯并噻唑-芳基丙烯酮共轭物，并对其细胞毒性和抑制微管蛋白聚合作用进行了评估。
• SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
  申请人：Wang Jeh-Jeng

  公开号：US20120215154A1

  公开（公告）日：2012-08-23

  The present invention provides a method of preparing a compound of formula 6 comprising: (a) reacting a compound of formula 1 with a compound of formula 2 to form a compound of formula 3 wherein X of formula 2 is Cl or OH; (b) treating the compound formula 3 with Lawesson's reagent to form a compound of formula 4 (c) reacting a compound of formula 4 with potassium ferricyanide to produce a compound of formula 5 and (d) performing catalytic reduction of nitro group of the compound of formula 5 with palladium on charcoal to generate the compound of formula 6, wherein R 1 of formulae 1-6 is H, C 1-10 alkyl, C 1-10 alkoxy or C 1-10 haloalkyl, and R 2 of formulae 1-6 is H or C 1-10 alkyl. The present invention also provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R 1 and R 2 are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue; wherein growth of the tumor is inhibited.

  本发明提供了一种制备6式化合物的方法，包括：(a) 将1式化合物与2式化合物反应以形成3式化合物，其中2式化合物的X为Cl或OH；(b) 用Lawesson试剂处理3式化合物以形成4式化合物；(c) 将4式化合物与氰化亚铁钾反应以生成5式化合物；(d) 用活性炭上的钯进行5式化合物的硝基团的催化还原，生成6式化合物，其中1-6式中的R1为H、C1-10烷基、C1-10烷氧基或C1-10卤代烷基，1-6式中的R2为H或C1-10烷基。本发明还提供了一种对患有至少一种肿瘤的患者进行光动力疗法的方法，包括以下步骤：向患者投药物学可接受的载体中的6式化合物（其中R1和R2如上所定义）；等待足够的时间以使给药的化合物被目标组织（至少一种肿瘤）吸收；照射患者身体含有目标组织的区域；从而抑制肿瘤的生长。
• Design, synthesis and antimetastatic evaluation of 1-benzothiazolylphenylbenzotriazoles for photodynamic therapy in oral cancer cells
  作者：Gopal Chandru Senadi、Chieh-Ming Liao、Kung-Kai Kuo、Jian-Cheng Lin、Long-Sen Chang、Jeh Jeng Wang、Wan-Ping Hu

  DOI：10.1039/c6md00034g

  日期：——

  We have designed and synthesized a new series of 1-benzothiazolylphenylbenzotriazoles 9a–p and studied their antimetastatic mechanism involved in photosensitive effects induced by UVA in oral cancer cell Ca9-22.

  我们设计并合成了一系列新的1-苯并噻唑基苯基三唑类化合物 9a–p 并研究了它们在口腔癌细胞Ca9-22中通过UVA诱导的光敏作用参与的抗转移机制。
• Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents
  作者：Wan-Ping Hu、Yin-Kai Chen、Chao-Cheng Liao、Hsin-Su Yu、Yi-Min Tsai、Shu-Mei Huang、Feng-Yuan Tsai、Ho-Chuan Shen、Long-Sen Chang、Jeh-Jeng Wang

  DOI：10.1016/j.bmc.2010.04.082

  日期：2010.8

  Photodynamic therapy (PDT) employing exogenous photosensitizers is currently being approved for treatment of basal cell carcinoma (BCC). 2-(4-Aminophenyl)benzothiazoles (6) consist of chromophoric structure and absorb light in the UVA (315–400 nm). These results encouraged us to design and synthesize a diversity of 2-phenylbenzothiazoles (6). Studies on the apoptotic mechanism involved in photosensitive effects

  使用外源光敏剂的光动力疗法（PDT）目前已被批准用于治疗基底细胞癌（BCC）。2-（4-氨基苯基）苯并噻唑（6）由发色结构组成，可吸收UVA（315-400 nm）中的光。这些结果鼓励我们设计和合成各种2-苯基苯并噻唑（6）。在本文中研究了UVC激活的6在BCC细胞中诱导的光敏效应所涉及的凋亡机制。用6 -UVA处理的细胞显示出一些凋亡特征，包括亚G1群体的增加，膜联蛋白V结合的显着增加以及caspase-3的激活。6-UVA诱导线粒体膜电位（Δ降低ψ公吨），并通过增强的ROS产生和胞外信号调节激酶（ERK）和p38 MAPK表达的促进磷酸ATP。这些结果表明6- UVA在涉及ERK和p38活化的线粒体过程中引起光敏作用，并最终导致BCC细胞凋亡。
• Antitumor Benzothiazoles. 8. Synthesis, Metabolic Formation, and Biological Properties of the <i>C</i>- and <i>N</i>-Oxidation Products of Antitumor 2-(4-Aminophenyl)benzothiazoles
  作者：Eiji Kashiyama、Ian Hutchinson、Mei-Sze Chua、Sherman F. Stinson、Lawrence R. Phillips、Gurmeet Kaur、Edward A. Sausville、Tracey D. Bradshaw、Andrew D. Westwell、Malcolm F. G. Stevens

  DOI：10.1021/jm990104o

  日期：1999.10.1

  2-(4-Aminophenyl)benzothiazoles 1 and their N-acetylated forms have been converted to C- and N-hydroxylated derivatives to investigate the role of metabolic oxidation in the mode of action of this series of compounds. 2-(4-Amino-3-methylphenyl)benzothiazole (1a, DF 203, NSC 674495) is a novel and potent antitumor agent with selective growth inhibitory properties against human cancer cell lines. Very low IC50 values (<0.1 mu M) were encountered in the most sensitive breast cancer cell lines, MCF-7 and T-47D, whereas renal cell line TK-10 was weakly inhibited by la. Cell lines from the same tissue origin, MDA-MB-435 (breast), CAKI-1 (renal), and A498 (renal), were insensitive to 1a. Accumulation and metabolism of la were observed in sensitive cell lines only, with the highest rate of metabolism occurring in the most sensitive MCF-7 and T-47D cells. Thus, differential uptake and metabolism of 1a by cancer cell lines may underlie its selective profile of anticancer activity. A major metabolite in these sensitive cell lines has been identified as 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole (6c). Hydroxylation of 1a was not detected in the homogenate of previously untreated MCF-7, T-47D, and TK-10 cells but was readily observed in homogenates of sensitive cells that were pretreated with 1a. Accumulation and covalent binding of [C-14]1a derived radioactivity was observed in the sensitive MCF-7 cell line but not in the insensitive MDA-MB-435 cell line. The mechanism of growth inhibition by 1a, which is unknown, may be dependent on the differential metabolism of the drug to an activated form by sensitive cell Lines only and its covalent binding to an intracellular protein. However, the 6-hydroxy derivative 6c is not the 'active' metabolite since, like all other C- and N-hydroxylated benzothiazoles examined in this study, it is devoid of antitumor properties in vitro.